RecruitingPhase 2NCT05333458
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
Studying Alveolar soft tissue sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Alice P ChenNational Cancer Institute LAO
- Intervention
- Atezolizumab(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2027
Study locations (13)
- Keck Medicine of USC Koreatown, Los Angeles, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05333458 on ClinicalTrials.govOther trials for Alveolar soft tissue sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548177Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06813417CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part SarcomaUniversity of Calgary
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06789081GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)AHS Cancer Control Alberta
- RECRUITINGNANCT03967834Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupInstitut Claudius Regaud
- RECRUITINGPHASE2NCT04332874A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT03016819Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)Advenchen Laboratories, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT03141684Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaNational Cancer Institute (NCI)